10x Genomics, Inc.
TXGHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframePart of the healthcare sector, 10x Genomics, Inc. (TXG) is listed under Health Information Services. The $5.55B market capitalization puts TXG squarely in mid-cap range for its industry. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
Market Cap
$5.55B
Beta
2.04
P/E (TTM)
—
P/E (Fwd)
211.64
EPS (TTM)
$-0.17
EPS (Fwd)
$0.21
ROE
-3.0%
ROA
-4.5%
Cash
$539.8M
Total Debt
$81.4M
Free CF
$124.5M
52W Change
260.0%
Annual Financials
Cash vs Debt
10x Genomics, Inc. holds $539.8M in cash against $81.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $124.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -3.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $516.4M (2022) to $642.8M (2025), reflecting a 24% increase over the period.
With a beta above 1.5, TXG tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, TXG has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TXG.